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AssemblyHuman papillomavirus (HPV) L1 self-assembles into virus-like particles (VLPs), which are the basis for the
two commercially available prophylactic vaccines. For one of them (Cervarix®) HPV 16 and 18 VLPs are being
produced in insect cells using the baculovirus expression system. However, due to low yield, production of
VLPs remains challenging for certain other PV types. Here we report that employment of a modiﬁed
baculovirus-based (MultiBac) expression system (Berger, I., Fitzgerald, D. J., and Richmond, T. J. (2004).
Baculovirus expression system for heterologous multiprotein complexes. Nat. Biotechnol. 22(12), 1583–7)
permits substantially improved VLP production of several PV types up to 40-fold. Highest VLP yields were
achieved when two copies of the L1 gene were expressed from independently controlled cassettes. We have
evaluated the production of HPV 57 L1 VLPs by the MultiBac system in more detail. Whereas the level of the
HPV 57 L1 protein was only slightly increased in comparison to the standard protocol we monitored a
strongly enhanced yield of HPV 57 VLPs. Our results imply that a critical concentration of L1 within the
producer cell is required for efﬁcient VLPs assembly. We show evidence that in addition a dominant negative
factor in conventionally produced recombinant baculoviruses contributes to differences in VLP yield. This
phenomenon might be attributable to the absence of the viral cysteine protease V-CATH in the modiﬁed
baculovirus system. We anticipate that use of the MultiBac expression system will facilitate capsid
production for papillomaviruses and thereby enable the generation of vaccines against infections by many of
the as yet untargeted HPV types.
© 2009 Elsevier Inc. All rights reserved.Introduction
Papillomaviruses (PVs) are a heterogeneous group of double-
stranded DNA viruses, which consists of more than 200 known types
(zur Hausen, 1999). PVs are host- and tissue-speciﬁc, with different
types featuring a characteristic differential biology. Cutaneous human
PVs (HPVs) primarily infect the skin, causing skin warts or epithelial
tumours whereas genital warts and anogenital cancer attribute to
infections by mucosal HPV types. Most prominently, virtually all
cervical cancer cases are etiologically linked to infections with so-
called high-risk HPVs with infections by types 16 and 18 alone
accounting for approximately 70% of them (Bosch et al., 2002; Clifford
et al., 2003; Munoz et al., 2003). Recently, two commercial vaccines
preventing de novo infections with HPV 16 and 18 have been licensed
(Lowy and Schiller, 2006). The vaccines that prevent CIN lesions
induced by the vaccine HPV types (Harper et al., 2004; Koutsky et al.,
2002; Mao et al., 2006; Villa et al., 2005) are based on the viral major
capsid protein L1, which has the intrinsic ability to self-assemble into
highly immunogenic virus-like particles (VLPs) with a diameter of
55 nm (Baker et al., 1991). For large-scale VLP production, both(M. Müller).
ll rights reserved.companies apply recombinant in vitro expression systems: Gardasil®
(Merck and Co., Inc.) and Cervarix® (GlaxoSmithKline Biologicals) are
produced in yeast and baculovirus-infected insect cells, respectively.
Applying baculovirus as vectors for recombinant protein expres-
sion has proven to be safe, easily manageable, and straightforward to
scale up (Cory and Hails, 1997; Ikonomou et al., 2003). Moreover, with
Cervarix®, a biopharmaceutical produced in baculovirus-infected
insect cells has been widely approved for the ﬁrst time. Thus far,
VLPs of a variety of different HPV types have been generated
successfully in insect cells (Christensen et al., 1996; Roden et al.,
1996; Suzich et al., 1995; Volpers et al., 1994). However in our attempt
to generate VLPs of cutaneous HPV types we have experienced a
comparatively low yield when compared to production of particles
from several different HPV 16 L1 constructs. Traditionally, recombi-
nant Autographa californica nuclear polyhedrosis virus (AcNPV) is
being generated by cotransfecting into insect cells the linearized
AcNPV genomewith a transfer plasmid carrying the gene of interest in
an expression cassette controlled by a late viral promoter. Upon
recombination of the expression cassette into the AcNPV genome,
progeny virus could be harvested and utilised for productive
infections. In recent years several improvements to baculovirus
vector-based expression systems have been reported. Flexibility has
been added by the availability of shuttle vectors allowing the
Fig. 1. Expression of HPV 57 L1 using the MultiBac expression system substantially increases VLP yield with high reproducibility. (A) Puriﬁed VLPs from infected insect cells. TN
High Five cells were infected with a conventionally generated baculovirus transgenic for HPV 57 L1 (conv57L1polh), or with MultiBac-based virus carrying HPV 57 L1 in the polh-
controlled cassette (mult57L1polh), in the p10-controlled cassette (mult57L1p10) or in both cassettes simultaneously (mult57L1polh+p10). Three days post-infection cells were lysed
and capsids were puriﬁed by a CsCl density gradient centrifugation. Equal volumes of the three gradient peak fractions per infection were loaded on an SDS-PAGE gel for
immunoblotting using an L1-speciﬁc MAb. As controls, mock capsid puriﬁcations were carried out after WT AcMNPV infection and after no infection and fractions corresponding
to the peak after infection with mult57L1polh+p10 were loaded. (B) To demonstrate reproducibility, six independent virus stocks were generated for each of the viruses
mult57L1polh, mult57L1p10, and mult57L1polh+p10. Independent TN High Five cell infections followed by capsid puriﬁcation were carried out. Three peak fractions per CsCl gradient
were pooled and loaded on SDS-PAGE gels, which were either Coomassie-stained and used for densitometric quantiﬁcation (top) or immunoblotted using an L1-speciﬁc MAb
(bottom).
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cassettes (Harris and Polayes, 1997). Moreover, the incorporation of
the recombinant expression cassette into the baculovirus genome by
site- and orientation-speciﬁc Tn7-mediated transposition has
improved and greatly simpliﬁed the progeny virus selection procedure
(Airenne et al., 2003; Luckow et al., 1993). On the other hand, protein
yield could be enhanced signiﬁcantly by the deletion of the genes
encoding for the AcNPV enzymes chitinase (chiA) and v-cathepsin (V-
CATH), which are involved in liquefaction of the host cell during
AcNPV pathogenesis, (Hom and Volkman, 2000; Kaba et al., 2004;
Slack et al., 1995; Suzuki et al., 1997). These improvements have been
combined in a recently described variant baculovirus expression
system named MultiBac (Berger et al., 2004).
Here we report that application of the novel baculovirus expres-
sion system permits substantially improved VLP production of several
PV types by multiple folds. We also provide a mechanistic analysis of
the superior VLP recovery rate achieved with this expression systemFig. 2. HPV 57 L1 produced with the MultiBac expression system assembles into properly fold
HPV 57 L1 in both expression cassettes were analysed by centrifugation through a linear
immunoblotted probing with L1-speciﬁc MAb. As calibration markers HPV 16 VLPs and cataimplying that a critical concentration of full-length L1 in the producer
cell is required for efﬁcient VLP assembly.
Results
MultiBac expression system enables improved yield of HPV 57 VLPs
The production of VLPs of certain HPV types, such as HPV type 16,
has been carried out successfully in insect cells by applying the
baculovirus expression system (Kirnbauer et al., 1993). However,
employment of conventional baculovirus-based expression systems
has proven to be arduous for certain other HPV types due to very low
yields. In our hands, one such problematic PV has been HPV 57, awart-
associated cutaneous α-papillomavirus.
A recently developed baculovirus-based expression system named
MultiBac allows for the synchronous expression of heterologous
proteins from two expression cassettes driven by the polyhedrined VLPs. Particles produced after infectionwith Multibac-based AcNPV recombinant for
sucrose gradient. The gradient was fractionated and samples of each fraction were
lase, a marker for capsomeres, were used.
Table 1
MultiBac expression system permits efﬁcient VLP production of various PV constructs and it enables production of mutant HPV constructs.
Conventional Multibac
polh polh p10 polh/p10
WT L1 proteins HPV2 ≤0.05 mg 0.2–0.4 mg 0.1–0.2 mg 0.8–1.5 mg
HPV3 0.1 mg N/A N/A 2.0 mg
HPV6a bdet N/A N/A 0.7 mg
HPV10 0.1 mg N/A N/A 4.0 mg
HPV11a ≤0.15 mg N/A N/A 1.2 mg
HPV18a ≤0.15 mg N/A 0.9 mg 1.3 mg
HPV27 ≤0.05 mg 0.15–0.4 mg 0.1–0.3 mg 0.8–1.2 mg
HPV57 ≤0.15 mg 0.6–1.2 mg 0.3–0.8 mg 1.5–2.8 mg
HPV77 0.5 mg N/A N/A 4.0 mg
BPV5 bdet N/A 1.2 mg 2.5 mg
BPV6 bdet N/A 1.2 mg 3.2 mg
Mutant L1 proteins HPV2 C172S, C422S L1 ≤0.05 mg 0.1–0.2 mg N/A 0.3–0.5 mg
HPV27 C173S, C424S L1 ≤0.05 mg 0.1–0.15 mg N/A 0.2–0.4 mg
HPV57 C173S, C4283S L1 ≤0.05 mg 0.1–0.2 mg N/A 0.2–0.35 mg
HPV16 L1E7 (1–60a) ≤0.05 mg 3.4 mg 5.1 mg 4.3 mg
The yield for the different baculovirus stocks infecting 108 High Five insect cells at an MOI of 2 is shown.
N/A: not analysed.
bdet: below detection limit.
a For these types, MultiBac-based viruses were generated with codon-modiﬁed L1 genes.
346 T. Senger et al. / Virology 388 (2009) 344–353(polh) and the p10 late viral promoters (Berger et al., 2004). We
produced MultiBac-based baculoviruses expressing full-length HPV
57 L1 from either of the two cassettes alone or concomitantly
(mult57L1polh, mult57L1p10, mult57L1polh+p10) as well as a con-
ventionally generated baculovirus recombinant for HPV 57 L1
(conv57L1polh) and carried out side-by-side infections of TN High
Five cells followed by capsid puriﬁcation by CsCl gradient puriﬁcation.
Whereas negligible amounts of HPV 57 L1 VLPs were detected in the
gradient fractions after infectionwith conv57L1polh, the HPV 57 L1 VLP
yield was substantially increased when the MultiBac-derived viruses
had been used for the infection (Fig. 1A). Strikingly, the L1 VLP yield
obtained after infection with mult57L1polh+p10 was considerably
higher than the combined yield after infection with mult57L1polh
and mult57L1p10.
To determine the variation of the three MultiBac-derived bacu-
lovirus vectors, six independent stocks were generated of each
of the three recombinant viruses mult57L1polh, mult57L1p10, and
mult57L1polh+p10. SDS-PAGE analysis of the samples collected after
independent infections with these virus stocks and subsequent cap-
sid puriﬁcation demonstrated reproducible yields for all three cons-
tructs with variations of only 1.5 to 2.4 fold (Fig. 1B).
To verify that the HPV 57 particles produced after infection with
MultiBac-derived AcNPVs are properly assembled, we characterized
them by sedimentation analysis. As exempliﬁed only for particles
obtained after infection with mult57L1polh+p10, their migration
pattern was virtually identical with the pattern exhibited by HPV 16
L1 VLPs obtained by applying the conventional expression system (Fig.
2). Almost all of the L1 was found in fractions corresponding to VLPs
indicative of the high capsid selectivity of the CsCl gradient
puriﬁcation. These data demonstrate that substantially increased
yields of bona ﬁde HPV 57 VLPs can be produced with the MultiBac
expression system.
MultiBac expression system permits efﬁcient particle production of
various PV types
To determine whether the MultiBac expression system also allows
for enhanced VLP production of PVs other than HPV 57, we generated
an extended panel of recombinant baculoviruses. Viruses carrying the
full-length L1 gene of HPV types 2, 3, 10, 27, 77 or BPV types 5 or 6
were either based on the conventional or on the MultiBac system.
Productive infections with each virus stock followed by capsid
puriﬁcation were performed and the VLP content in the yield was
quantitated following SDS-PAGE analysis and Coomassie-staining. Foreach of the above PV, the VLP yield was increased between 8 and 40
fold when the MultiBac expression system was used compared to
application of a conventional system (Table 1). Noticeably, in our
hands, VLP production for some of these PVs, such as BPV 5 and 6,
failed entirely when conventional baculovirus-based expression
systems were applied. Consistent with the ﬁndings for HPV 57, the
VLP yield for all tested PVs was highest when L1 was expressed from
both, the polh and the p10 cassette concomitantly. We also aimed to
increase the VLP recovery rate for HPV 6, 11, and 18, for which
production used to be unsatisfactory in our laboratory. Employment of
the Multibac expression system improved VLP yield considerably for
all three types (Table 1). However, only a non-stringent comparison
between the different expression systems is feasible as these HPV L1s
were introduced into the MultiBac-based recombinant AcNPVs as
codon-modiﬁed L1 genes. To illustrate the integrity of the produced
capsids, they were further puriﬁed by heparin afﬁnity chromatogra-
phy and analysed by electron microscopy (Fig. 3).
In addition to the production of VLPs using wild-type L1 proteins
we also expressed genes encoding for modiﬁed L1 proteins using the
MultiBac expression system. For the production of HPV 2, 27, and 57
capsomeres, we replaced two highly conserved cysteine residues of L1
involved in intercapsomeric disulﬁde bond formation with serine
residues (Li et al., 1998; Sapp et al., 1998), and generated the
respective recombinant baculoviruses either conventionally or with
the MultiBac system. Additionally, AcNPVs transducing an HPV 16
L1E71–60 fusion protein resulting in formation of chimeric VLPs
(cVLPs) (Muller et al., 1997) were prepared. In our hands, production
of particles composed of either of these proteins has proven rather
inefﬁcient so far. However, employment of the MultiBac expression
system resulted in up to 0.5 mg of capsomeres and 4.3 mg of cVLPs per
standard puriﬁcation (Table 1) underscoring the efﬁcacy of the
MultiBac system also for the production of mutant L1-based PV
particles.
Increased VLP yield and L1 expression levels do not directly correlate
The VLP yield was most favourable with MultiBac-based baculo-
viruses that induced L1 expression from the polh- and the p10-
controlled multiple cloning sites concomitantly. To address the
question whether simply different expression levels of the L1 protein
correlate with the improved VLP yield, we infected TN High Five cells
with conv57L1polh, mult57L1polh, mult57L1p10, and mult57L1polh+p10.
Three days post-infection, the HPV 57 L1 content in the cell lysates
was determined by immunoblotting. We observed that L1 expression
347T. Senger et al. / Virology 388 (2009) 344–353levels were similar in theMultiBac-based virus-infected cells, whereas
lower amounts of L1 protein were detectable in the cells infected with
conv57L1polh (Fig. 4A). In addition, two L1 protein species of different
sizes (55 and 45 kDa) were detected in the conv57L1polh-infected
cells, possibly a result of proteolytic degradation.
Quantiﬁcation of total HPV 57 L1 protein levels three days post-
infection and of HPV 57 VLPs obtained after subsequent capsid
puriﬁcation indicates that slight differences in L1 concentrations
correlate with pronounced disparities in VLP yield (Fig. 4B). We also
analysed the L1 expression in TN High Five cells infected with the
same set of recombinant AcNPVs by immunoﬂuorescence microscopy
using an HPV 57 L1-speciﬁc MAb (T. Senger unpublished). Consistent
with the biochemical analyses of L1 expression levels (Fig. 4A) we
detected the highest amounts of HPV 57 L1 in cells infected with
double-recombinant MultiBac (single-recombinant MultiBac: inter-
mediate amounts of L1, conventionally generated: lowest amounts of
L1) viruses (Fig. 4C). However, as evident by both assays, HPV 57 L1Fig. 3.MultiBac expression system permits VLP production of various PV types. VLPs from H
were produced upon infection with MultiBac-based AcNPV recombinant for the respective L
and heparin afﬁnity chromatography. Samples were analysed by electron microscopy. As con
parallel infection followed by the same puriﬁcation protocol. Bars indicate 50 nm in all panexpression levels correlate disproportionately with the increase in VLP
recovery rate upon employment of MultiBac-based viruses suggesting
that superior VLP yields are not solely attributable to elevated L1
expression.
It has been reported that L1 transcript quality and quantity can
have a major impact on recombinant VLP production (Neeper et al.,
1996). To evaluate whether the differences of expressed L1 amounts
upon infectionwith conventional or MultiBac-derived AcNPVs are due
to differences in the transcript levels, we isolated poly(A)+-RNA from
the TN High Five cells three days post-infection and determined the
amount of L1 transcripts using a radiolabelled HPV 57 L1-speciﬁc
probe. Surprisingly, two distinct L1-speciﬁc transcript species of
different sizes were identiﬁed in cells expressing L1 from a polh-
controlled MultiBac-based cassette (Fig. 5). In comparison, a con-
siderably longer transcript species of much lower abundance was
detected in cells in which L1 expression was driven from a p10-
controlled cassette transduced by MultiBac virus. As expected, allPV 2, HPV 3, HPV 6, HPV 10, HPV 11, HPV 18, HPV 27, HPV 57, HPV 77, BPV 5, and BPV 6
1 gene in both multiple cloning sites. VLPs were puriﬁed by CsCl gradient centrifugation
trol, conventionally generated baculovirus inducing HPV 16 L1 expressionwas used for a
els.
Fig. 4. A slight increase in HPV 57 L1 expression levels strongly enhances VLP yield. (A) TN High Five cells were infected with a conventionally generated baculovirus transgenic for
HPV 57 L1 (conv57L1polh), or with MultiBac-based virus carrying HPV 57 L1 in the polh-controlled cassette alone (mult57L1polh), in the p10-controlled cassette alone (mult57L1p10)
or in both cassettes simultaneously (mult57L1polh+p10). Three days post-infection L1 expression was determined in cell lysates by western blotting. (B) Quantiﬁcation of HPV 57 L1
expressed three days post-infection and of HPV 57 VLPs after subsequent capsid puriﬁcation. Protein amounts were quantiﬁed by densitometric means after SDS-PAGE analysis. (C)
Detection of HPV 57 L1 in infected insect cells by immunoﬂuorescence. TN High Five cells were infected with conv57L1polh, mult57L1polh, mult57L1p10, or mult57L1polh+p10. Three
days post-infection, cells were immunostained using the HPV 57 L1-speciﬁc MAb TS57-1 and Fluor 488-conjugated goat anti-mouse IgG.
Fig. 5. HPV 57 L1-speciﬁc transcript levels in insect cells infected with baculoviruses
generated with the conventional or the MultiBac system. TN High Five cells were
infected with WT AcMNPV, with a conventionally generated baculovirus transgenic for
HPV 57 L1 (conv57L1polh), or with MultiBac-based virus carrying HPV 57 L1 in the polh-
controlled cassette alone (mult57L1polh), in the p10-controlled cassette alone
(mult57L1p10) or in both cassettes simultaneously (mult57L1polh+p10). Three days
post-infection cellular poly(A)+-RNA was isolated, size-fractionated on an agarose gel,
Northern blotted, and probed for HPV 57 L1 transcripts using a radiolabelled probe.
Speciﬁcity of the applied probe was veriﬁed by reverse transcription of the poly(A)+-
RNA, HPV 57 L1 transcript-speciﬁc PCR ampliﬁcation and sequencing of the ampliﬁed
cDNA.
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cells. Importantly, the presence of a single highly abundant L1
transcript in cells infected with conv57L1polh indicates that the
observed two protein species are likely due to posttranscriptional
events. Whereas we did not further analyse the structure of the
different transcripts we conclude from these data that differences in
L1 expression are not caused by different promoter activities and/or
RNA stability.
Conventional baculovirus confers a functionally dominant negative
factor
Thewild-type baculovirus genome encodes for a cysteine protease,
V-CATH, which is involved in the destruction of host insect cell tissue
in the course of in vivo replication of AcNPV (Slack et al., 1995). An
essential factor required for V-CATH activation is represented by the
chitinase chiA (Hom and Volkman, 2000). Both genes have been
inactivated in the baculovirus genome utilised in the MultiBac
expression system (Berger et al., 2004). We assumed that conven-
tional AcNPVs carry a dominant negative factor for production of PV
L1. To verify this hypothesis, we produced conventional or MultiBac-
based AcNP viruses, both recombinant for the Green Fluorescent
Protein (GFP) under the control of the polh promoter (convGFPpolh,
multGFPpolh) for coinfection studies. First, we ascertained by immu-
noﬂuorescence microscopy that TN High Five cells can be coinfected
with at least two different AcNPVs leading to ectopic expression of
GFP and HPV 57 L1 within the same cell as exempliﬁed here for
convGFPpolh and mult57L1polh coinfection (Fig. 6A). Next, we infected
TN High Five cells either with conv57L1polh or mult57L1polh alone or
together with convGFPpolh or multGFPpolh and quantiﬁed the GFP
and HPV 57 L1 amounts in the cell lysates and the amount of VLPs
in the CsCl gradient fractions after capsid puriﬁcation. Results are
shown in Fig. 6B. As described above, expression levels of the HPV 57L1 protein differed only slightly upon infection with conv57L1polh or
mult57L1polh alone, whereas a 13-fold higher VLP yield was achieved
after infection with the mult57L1polh. However, when mult57L1polh
was coinfected with convGFPpolh, HPV 57 VLP recovery rate declined
to levels comparable to those obtained after conv57L1polh single
infection whereas levels of L1 protein were only slightly affected. In
349T. Senger et al. / Virology 388 (2009) 344–353contrast, upon coinfection with mult57L1polh and multGFPpolh, HPV 57
VLP yield was not decreased. Conversely, coinfection with conv57L1polh
and convGFPpolh resulted in low VLP yield, yet, coinfection with
conv57L1polh and multGFPpolh surprisingly rescued the VLP yield. In
terms of GFP expression, highest levels were detected in cells infected
with the two different MultiBac-based viruses (i.e. multGFPpolh and
mult57L1polh), intermediate levels were observed upon coinfection of
one MultiBac-derived and one conventionally generated virus (i.e.
conv57L1polh and convGFPpolh), and low level GFP expression was
detected when the two conventionally produced viruses (i.e.
multGFPpolh and conv57L1polh or convGFPpolh and mult57L1polh)
were used for coinfection. These data illustrate, that a dominant
negative factor is conferred by conventionally generated baculo-
viruses leading to a decrease in HPV 57 L1 expression levels and, most
notably, VLP yield.Fig. 6. Conventionally produced AcNPV confers a dominant negative effect on the stability
immunoﬂuorescent staining. TN High Five cells were coinfected with convGFPpolh and mult
MAb TS57-1 and Cy3-conjugated goat anti-mouse IgG and DAPI. (B) TN High Five cells w
convGFPpolh or multGFPpolh. The amounts of GFP and HPV 57 L1 in the cell lysates and the am
followed by immunoblotting or by Coomassie-staining and densitometric quantiﬁcation ofTo investigate whether the negative effect on HPV 57 L1 VLP yield
upon infectionwith conv57L1polh can be rescued by an increased MOI,
we infected TN High Five cells with conv57L1polh or mult57L1polh at
MOIs between 0.01 and 20 and analysed protein amount and VLP
yields. A second L1 species of reduced size after infection with
conv57L1polh occurred independently of MOI (Fig. 7). In contrast, only
the full-length L1 protein was detected in cells infected with
mult57L1polh. For both AcNPVs, increased MOIs lead to elevated L1
expression, yet, quantiﬁcation of full-length L1 revealed higher L1
expression levels after infection with mult57L1polh (Figs. 7A and B).
For this virus, highest VLP yield was achieved at MOIs between one
and two and decreased with higher MOIs. No such prominent optimal
MOI was observed for conv57L1polh. Here, VLP yield increased only
slightly with elevated MOIs peaking at an MOI of 10 consistent with
the hypothesis of a dominant negative factor conferred by theof the recombinant protein upon coinfection. (A) Detection of double infected cells by
57L1polh. Three days after the infection, cells were stained with the HPV 57 L1-speciﬁc
ere infected either with conv57L1polh or with mult57L1polh alone, or together with
ount of VLPs in the peak fractions after capsid puriﬁcationwere evaluated by SDS-PAGE
HPV 57 L1 and GFP.
Fig. 7. Dominant negative effect conferred by conventionally produced AcNPV is independent of MOI. (A) Detection of HPV 57 L1 expressed in TN High Five cells upon infection
conv57L1polh or mult57L1polh at different MOI. Three days after the infection, cells were lysed and equal volumes of the lysates were immunoblotted probing with L1-speciﬁc MAb.
(B) Quantiﬁcation of HPV 57 L1 expression and HPV 57 VLP yield after infection with different MOI. The amounts of HPV 57 L1 in the cell lysates and the amount of VLPs in the peak
fractions after capsid puriﬁcation were evaluated by SDS-PAGE followed by immunoblotting or by Coomassie-staining and densitometric quantiﬁcation. The respective values are
plotted over the MOI applied for conv57L1polh and mult57L1polh.
350 T. Senger et al. / Virology 388 (2009) 344–353conventionally generated AcNPVwhich cannot be compensated for by
a higher virus dose.
As the major difference between conventionally produced and
MultiBac-based viruses is the absence of V-CATH activity conferred by
particles produced by the MultiBac system, it is likely that this
dominant negative effect is indeed caused by V-CATH, particularly
given the occurrence of truncated L1 speciﬁcally in cells infected with
conventionally produced AcNPV.
Discussion
So far, the modiﬁed baculovirus expression system named Multi-
Bac has been used primarily for the expression of heterologous
multiprotein complexes (Berger et al., 2004; Bieniossek et al., 2008;
Fitzgerald et al., 2006; Fitzgerald et al., 2007). We report here that
employment of the MultiBac system permits enhanced VLP produc-
tion of various PVs. We show that strongly increased VLP yield
coincides with slightly elevated L1 expression. Our ﬁndings suggest
that a dominant negative factor inherent to conventional AcNPV
contributes to differences in L1 production. We conclude that the
absence of V-CATH activity in MultiBac infections favours L1 yield.
We compared the VLP yield for various PV types after infection
with conventionally generated or MultiBac-based AcNPVs. For HPV
types 2, 3, 10, 27, 57, 77, and for BPV types 5 and 6, the yield achieved
using theMultiBac systemwas improved up to 40-fold (Fig. 1, Table 1).
With the exception of HPV 2 (Cubie et al., 1998) VLP production for
any of these PVs has not yet been reported. Proper capsid structure
was veriﬁed by sedimentation analysis and transmission electron
microscopy (Figs. 2 and 3). For HPV types 6, 11, and 18 VLP production
in insect cells has been reported previously (Roden et al., 1996).
Furthermore, for these three HPV types, we introduced codon-modiﬁed L1 genes into the AcNPV genome for the generation of
MultiBac-based virions whereas the conventional AcNPVs were
generated using unmodiﬁed L1 genes. Hence, a direct comparison of
the VLP yields upon infection with conventional and MultiBac viruses
cannot be made. However, in our laboratory VLP production of HPV
types 6, 11, and 18 was all but satisfactory, yet, large amounts of VLPs
could be generated applying the MultiBac system. Thus, our ﬁndings
suggest that theMultiBac system allows for yielding VLP production of
multiple PVs.
We also expressed mutant L1 constructs that had previously
proved inefﬁcient in particle production. The enhanced yields
achieved using the MultiBac system highlight its applicability for
production of VLP-related particles such as the candidate prophylactic
and therapeutic vaccine HPV 16 L1E71–60 cVLPs. A closely related
cVLP-based vaccine (L1E71–55) has already proven safe in a phase 1/2
clinical trial (Kaufmann et al., 2007).
The MultiBac system enables expression controlled either by the
polyhedrin (polh) or the p10 promoter. Both drive protein expression
very late in the AcNPV life cycle with the activation of the p10 gene
preceding the activation of the polh gene by few hours (Roelvink et al.,
1992). We observed largely similar intracellular HPV 57 L1 levels upon
polh- and p10-driven expression. Simultaneous expression from both
multiple cloning sites resulted in slightly elevated HPV 57 L1
production (Fig. 4). These ﬁndings are in accordance with DiFalco
et al. (1997) who reported similar results upon single and combined
polh- and p10 promoter-controlled expression of insulin-like growth
factor-interleukin-3 chimeras. The slight increase in HPV 57 L1 levels
due to expression from both cassettes manifests itself in signiﬁcantly
enhanced VLP yield (Figs. 1, 4). This phenomenon is suggestive of a
VLP assembly process that is sensitive for a minimal L1 concentration.
Indeed, an analysis of the HPV11 capsid formation kinetics in vitro has
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and that a critical cooperativity of pentamers is necessary to initiate
stable nucleation for further assembly (Casini et al., 2004). Hence, our
ﬁndings suggest a similar capsid assembly kinetics in the in vivo
environment.
For HPV 11, low VLP yield upon L1 expression in yeast has been
attributed to a truncation of the corresponding mRNA (Neeper et al.,
1996). Therefore, we analysed the HPV 57 L1 transcripts after
infection with conventionally generated or MultiBac-derived AcNPVs.
In our analysis no truncated HPV 57 L1 transcripts were observed.
However, L1 mRNA lengths differed considerably upon infection with
conv57L1polh, mult57L1polh, mult57L1p10, or mult57L1polh+p10 (Fig. 5).
The mRNA of about 3 kb length for the conv57L1polh-infected and the
mRNA of about 2 kb length for mult57L1polh-infected cell isolates
were consistent with transcription initiation and termination at the
annotated sites. On the other hand, the additional transcript of about
5 kb upon mult57L1polh infection and the single mRNA of roughly
11 kb after infection with mult57L1p10 were not expected. The
occurrence of several transcript species of unexpected sizes has
been described previously for the recombinant expression of inﬂuenza
virus haemagglutinin in insect cells (Possee, 1986). Such mRNA may
result from run-on transcription. We hypothesize that mRNA
transcripts of lengths longer than about 2 kb may be dispensable
and even inhibitory for efﬁcient VLP production. Their avoidance
should be the aim of future optimization efforts. Nonetheless, the
abundance of the polh- and p10-derived transcripts does not correlate
closely with the corresponding L1 expression levels (Fig. 4) indicating
that translation rate and protein stability have a stronger impact on
VLP yield than quantitative effects on the transcript level.
Infection with conventionally generated AcNPV entails the pro-
duction of a single HPV 57 L1mRNA transcript whereas two distinct L1
protein populations occur, one of which is smaller than full-length L1
(Figs. 4 and 5). In contrast, only full-length L1 was found in lysates
from MultiBac AcNPV-infected cells. Thus, the L1 protein seems to be
degraded speciﬁcally in cells infected with conventional AcNPVwhich
results in a decreased full-length L1 concentration. However, the
superior performance achieved by the MultiBac-based recombinant
AcNPV may not be solely accounted to elevated L1 expression or
stability.
Double infection of TN High Five cells with AcNPVs recombinant
for HPV 57 L1 or for GFP leads to low protein expression upon
infection with two conventional virus pools, intermediate expression
upon infection with one conventional and one MultiBac virus pool,
and high expression upon infection with two MultiBac virus pools
(Fig. 6). As expected, differences in L1 protein levels are reﬂected as
correspondingly different VLP recovery rates in an ampliﬁed manner.
Accordingly, coinfection of MultiBac virus with a conventionally
derived AcNPV reduces recombinant protein expression in the host
cell implicating that conventional viruses confer a dominant negative
factor, which is absent in MultiBac-based particles. A major distinction
between the employed baculovirus expression systems is the deletion
of the genes encoding for chiA and V-CATH, which was shown to
enhance protein yield due to depletion of viral cysteine protease
activity (Hom and Volkman, 2000; Kaba et al., 2004; Slack et al., 1995;
Suzuki et al., 1997). The detection of truncated L1 only in the cells
infected with conventionally generated AcNPV is in accordance with
these reports. Therefore, the dominant negative factor conveyed by
conventional baculovirus may be V-CATH activity alleviating intracel-
lular L1 protein and leading to markedly decreased VLP yield.
However, in addition to the disproportionate correlation between L1
concentration and VLP production, a complementary effect might
impact on the system efﬁcacy. Truncated L1 proteins occurring in cells
infected with conventionally generated virus may exert an inhibitory
effect as abortive components in the process of capsid assembly. This
hypothesis is in line with the observation that increased MOI, also
increasing the hypothesized negative factor, does not enhance VLPyield signiﬁcantly despite considerably elevated full-length L1
expression levels (Fig. 7).
In the case of coinfection with conv57L1polh and multGFPpolh the
achieved HPV 57 VLP yield was higher than that after infection with
conv57L1polh alone. This rescuing effect would be consistent with the
presence of a dominant negative factor conveyed by conventional
AcNPVs as interaction of the truncated V-CATH or chiA conferred by
the MultiBac-based virus may inhibit activity of the functional V-
CATH or chiA introduced by the conventional virus. Note that chiA is
required for the activity of the V-CATH protease (Hom and Volkman,
2000). In fact, according to our information, both enzymes have
been inactivated by homologous recombination targeting the
c-terminal part of either gene and leaving at least half of the
protein-coding region intact (information was obtained from the
international patent application WO2005085456). Such obstructing
interaction, however, is likely to depend on stoichiometry as
indicated by the decreased VLP yield in case of coinfection with
convGFPpolh and mult57L1polh.
Infectionwith mult57L1polh at different MOIs revealed a virus dose
optimal for HPV57 L1 VLP production betweenMOIs one and two (Fig.
7). At MOIs N2 the corresponding VLP yield was substantially
decreased. Such decreased recovery rates at comparatively low MOIs
may be due to formation of very high concentrations of nucleation
centres consuming most L1 proteins before VLP assembly is
completed. This phenomenon has been described as “kinetic
trapping” for assembly of HBV capsids (Zlotnick and Stray, 2003).
It has been well described that VLP yield of different HPV 16
variants varies considerably using a baculovirus-mediated in vitro
expression system (Touze et al., 1998). Hence, it is not unexpected that
VLPs from different PVs are not equally straightforward to produce. In
this report we provide evidence for more efﬁcient VLP production of
various PV types. In our study we show for the ﬁrst time, that efﬁcient
production of VLPs from alpha-papillomaviruses can be achieved. For
some of these PV types it had been problematic to produce large
amounts of VLPs in our laboratory.
One issue not speciﬁcally addressed in our investigations is the
genetic stability of MultiBac baculoviruses, which is an important
aspect in the large-scale VLP production. In our study we compared
multiple independently generated viruses containing single and
double L1 insertions. These stocks led to consistent L1 expression
after serial passage indicating at least mid-term genetic stability even
when two copies of L1 are present. We anticipate that use of the
MultiBac expression systemwill facilitate capsid production in general
and particularly for challenging PV types and thereby enable the
generation of vaccines preventing infections by many of the as yet
untargeted HPVs.
Materials and methods
Cells and viruses
Spodopteria frugiperda 9 (Sf9; Invitrogen) cells were grown in
suspension at 27 °C andmaintained on Grace's insect medium (Gibco)
supplemented with 10% foetal bovine serum (FCS; Sigma) and
Pluronic F-68 (Sigma). Trichoplusia ni (TN) High Five cells (Invitrogen)
were cultivated in Ex-Cell™ 405 serum-free medium (SAFC Bios-
ciences) at 27 °C. The WT AcMNPV was obtained from BD Biosciences,
the recombinant viruses were produced as described below.
Generation of baculovirus recombinants
All point mutations in the L1 genes were introduced using the
QuikChange® Multi Site Directed Mutagenesis Kit (Stratagene). The
generation of the chimeric HPV 16 L1E71–60 construct has been
described previously (Muller et al., 1997). Full-length or mutated L1
genes were cloned into the transfer plasmids pVL1392 (Invitrogen) or
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introducing restriction sites. All constructs were conﬁrmed by DNA
sequencing.
Recombinant AcNPVs referred to here as produced with a
conventional system were generated as described in Muller et al.
(1995). Brieﬂy, 2 μg of the respective transfer plasmid and 0.2 μg of
linearized DiamondBac™ baculovirus DNA (Sigma) were cotrans-
fected by calcium phosphate precipitation into 5×106 Sf9 cells.
To generate the MultiBac recombinant AcNPVs, the strategy
explicitly outlined previously (Fitzgerald et al., 2006) was applied.
Brieﬂy, 10 ng of recombinant plasmid was transformed into
DH10MultiBac cells. Positive clones, as identiﬁed by blue/white
selection, were ampliﬁed and MultiBac bacmid DNA was isolated.
Onemicrogram of bacmid DNAwas transfected into 5×106 Sf9 cells by
calcium phosphate precipitation.
All recombinant Ac viruses were ampliﬁed at least three times
before their employment for a productive infection of TN High Five
cells. The titer of all AcNPVs was determined by a plaque assay as
described previously (Matsuura et al., 1987).
Virus-like particle production and puriﬁcation
PV virus-like particles (VLPs) were produced as described in
Muller et al. (1997). Brieﬂy, 2×108 TN High Five cells were infected
with WT or recombinant baculovirus at an MOI of 2 unless indicated
otherwise. Three days post-infection, cells were harvested and lysed
by sonication. Subsequently, the lysate was cleared by centrifugation,
layered onto a two-step gradient with 14 ml of 40% sucrose on top of
8 ml of a 57.5% CsCl solution, and centrifuged for 3 h at 96,500 ×g at
10 °C in a SW32 rotor (Beckman). The interphase was collected and
transferred into a Quick-seal tube (Beckman). A CsCl gradient was
produced by a 16 hour-centrifugation at 184,000 ×g at 20 °C in a Sorval
TFT 65.13 rotor and fractionated into 1 ml specimen. Purity and L1
content of the collected fractions were assessed by SDS-PAGE and
Coomassie-staining.
The peak fractions were pooled, dialyzed against 50 mM Hepes
(pH 7.4, 0.3 M NaCl), and cleared from residual debris by centrifuga-
tion at 20,000 ×g for 10 min at 4 °C. The samples were further puriﬁed
by afﬁnity chromatography using 1 ml HiTrap™ Heparin HP columns
(GE Healthcare). Elution of VLPs was carried out with 50 mM Hepes
(pH 7.4) containing 1 M NaCl. The eluates were analysed by SDS-PAGE
and Coomassie-staining and western-blot analysis. The capsid quality
was veriﬁed by electron microscopy.
Detection and quantiﬁcation of L1 proteins
PV L1 proteins were analysed by SDS-PAGE and stained with
colloidal Coomassie dye (GelCode Blue stain reagent, Pierce) or
immunoblotted and probed with the anti-L1 monoclonal antibody
(MAb) MD2H11. L1 protein concentrations were determined using
image densitometry software ImageJ (http://rsb.info.nih.gov/ij/) and
bovine serum albumin or HPV 57 L1 as standards for the Coomassie-
stained SDS-PAGE gels or the immunoblots respectively.
Sedimentation analysis
Samples were loaded onto a linear gradient of 5%–50% sucrose in
50 mM Hepes (pH 7.4) containing 0.5 M NaCl and centrifuged at
222,000 ×g for 3 h at 4 °C using a SW41 Ti rotor. Fractions (600 μl)
were collected from the bottom of the gradient and analysed by SDS-
PAGE and immunoblotting.
Electron microscopy
VLPs (100 ng) were applied onto carbon coated grids and stained
with 2% uranyl acetate. Grids were analysed using a transmissionelectron microscope CM200 FEG (FEI) operating at 200 kV. Pictures
were taken at a 27,000 fold magniﬁcation using a 2 k×2 k CCD
camera.
Generation and puriﬁcation of the monoclonal antibody TS57-1
For the generation of MAb TS57-1 BALB/c mice were immunized
s.c. three times in 4 week intervals with 10 μg HPV 57 VLPs
emulsiﬁed in complete Freund's adjuvant for the ﬁrst injection or
incomplete Freund's adjuvant for the subsequent injections. An
additional boost was performed i.p. three days before the mice were
sacriﬁced and the spleens were isolated. Fusion of spleen cells with
myeloma cell line SP2/0-Ag14 (ratio 5:1) was carried out using
polyethylenglycol (PEG; Sigma-Aldrich) (Kohler and Milstein, 1975).
Hybridoma supernatants were screened by enzyme-linked immu-
nosorbent assay (ELISA) using GST-L1 fusion protein as described in
Sehr et al. (2001).
The hybridoma supernatant was puriﬁed by afﬁnity chromato-
graphy using GammaBind™Plus Sepharose™ (GE Healthcare). Bound
antibodies were eluted with 100 mM glycine (pH 3.0), collected in
1 ml fractions, and 50 μl of 1 M Tris (pH 8.0) was added to each
fraction. Highly reactive fractions as identiﬁed by GST-capture ELISA
were pooled and dialyzed overnight against PBS. Protein content was
determined by Bradford assay and purity was veriﬁed by SDS-PAGE
followed by Coomassie-staining.
Immunoﬂuorescence
On 18 mm round cover slips, 5×105 Sf9 cells were seeded and
infected with recombinant or WT baculovirus. TN High Five cells were
infected in suspension and, after a three-day incubation, 1×104 cells
were centrifuged onto microscope slides by means of cytospin
(Shandon). Cells were ﬁxed with 4% paraformaldehyde (PFA) and
washed three times with phosphate buffered saline (PBS). Immunos-
taining was performed with the MAb TS57-1 as primary antibody
(1:500) and Cy™3-linked goat anti-mouse IgG (1:200) (GE Health-
care) or Fluor 488-conjugated goat anti-mouse IgG (1:300) (Invitro-
gen) as secondary antibodies. Cells were washed ﬁve times with PBS
after incubation with each antibody. DAPI (Sigma) was used to stain
the nuclei. As mounting reagent ProLong® Gold (Invitrogen) was
applied. Digital images were captured using a Leitz DM-RBE micro-
scope (Leica) equipped with an F-View camera (Olympus) controlled
by cellF software (Olympus).
Transcript analysis
RNA from 3×106 infected TN High Five cells was isolated using the
RNeasy kit (Qiagen). Poly(A)+-RNA was selected using DynaBeads
oligo(dT)25 (Invitrogen). For Northern blot analysis, 2 μg of the poly
(A)+-RNA was size-fractionated on a denaturing agarose gel and
transferred to a Hybond membrane (GE Healthcare). A probe was
generated by radiolabelling of PCR-ampliﬁed full-length HPV 57 L1
DNA with an α[32P]ddNTPs/dNTP blend using the random priming
method (GE Healthcare). For sequence analysis, poly(A)+-RNA
samples were reverse transcribed and ampliﬁed applying the
Phusion™ RT-PCR kit (Finnzymes) or the LongRange 2Step RT-PCR
kit (Qiagen) for transcript specimen b2500 nucleotides or N2000
nucleotides respectively. In both cases, the forward primer CATGA-
CATTCTGGGATGTGG and an oligo(dT) reverse primer were applied for
the ampliﬁcation reaction. The same primer set was used to verify the
sequence identities of the obtained cDNAs.
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